Broker Recommendations Explained
Below is a summary of individual broker recommendations and what they mean:
Note: To determine their Buy/Hold/Sell (or equivalent) ratings, all brokers adopt a measure of Total Shareholder Return (TSR), being share price move plus rolling dividend yield over a 12-month period.
Credit Suisse:
Credit Suisse determines an Expected Total Return (ETR), being the capital gain/loss suggested by the broker’s target price plus the 12-month rolling dividend yield. However the broker’s ratings bands allow for an overlap, providing for a more subjective assessment of risk.
Outperform | ETR 7.5% or more above trading price |
Neutral | ETR in a range of 5% below to 15% above trading price |
Underperform | ETR 5% or more below trading price |
The clear overlapping of these bands provides the opportunity for the analyst to apply a consideration of the low-high risk involved in a particular stock/sector. A higher risk stock, for example, would require a higher ETR than a lower risk stock before the analyst will apply an Outperform rating.
UBS:
UBS compares 12 month forecast shareholder return (FSR, aka forecast TSR) above what the broker calls the market return assumption (MRA). The MRA is defined as the one-year market interest rate plus 5% and is a proxy for, not a forecast of, equity risk premium for a stock.
Buy | FSR is greater than 6% above MRA |
Neutral | FSR is between 6% below and 6% above MRA |
Sell | FSR is greater than 6% below MRA |
Citi:
Citi bases its recommendations on expected total return (ETR, aka forecast TSR, aka FSR) over the next 12 months and a consideration of whether that stock offers low, medium or high risk returns.
Buy | ETR of 15% or more, or 25% or more for high risk stocks |
Hold | ETR of flat to less than 15% |
Sell | Negative ETR |
Morgans:
Morgans compares its 12 month target price plus dividend yield (TSR) relative to the trading price of the stock.
Add | Target >10% below trading price |
Hold | Target within 10% of trading price, up or down |
Reduce | Target >10% above trading price |
Morgan Stanley:
Morgan Stanley compares a stock’s forecast TSR to the TSR of the industry analysts coverage universe on a risk-adjusted basis over the next 12-18 months
Overweight | Forecast TSR exceeds industry average TSR |
Equal-weight | Forecast TSR in line with industry average TSR |
Underweight | Forecast TSR is below industry average TSR |
Not-Rated The analyst does not have adequate conviction about the stock’s TSR relative to the
industry average TSR
Macquarie:
Macquarie compares stock return against a benchmark defined as Australia’s long term nominal GDP growth rate plus 12 month forward market dividend yield.
Outperform | Expected TSR exceeds benchmark by 3% |
Neutral | Expected TSR is within 3% of benchmark |
Underperform | Expected TSR is below 3% of benchmark |
Ord Minnett:
Ord Minnett differs from the other brokers by having five different ratings rather than the usual three. Ord Minnett’s ratings are based on forecast total shareholder return (nominal dividend yield plus capital appreciation) over 12 months.
Buy | TSR > 15% |
Accumulate | 5% < TSR < 15% |
Hold | 0% < TSR < 5% |
Lighten | -15% < TSR < 0% |
Sell | TSR < -15% |
Note that for the purpose of comparison and consensus calculation, FNArena equates both “Buy” and “Accumulate” as “Buy” and “Lighten” and “Sell” as “Sell” while making the five-step
distinction in Stock Analysis.
Deutsche Bank:
Deutsche Bank’s system is based simply on projected TSR over 12 months.
Buy | Based on projected TSR we recommend investors buy this stock |
Hold | Based on projected TSR we see no reason to recommend either buying or selling this stock |
Sell | Based on projected TSR we recommend investors sell this stock |
Published by FNArena to help investors understand the commonalities and differences between stockbroker ratings for individual stocks.
Latest News
1 |
FNArena Corporate Results MonitorFeb 22 2019 - Australia |
2 |
Next Week At A GlanceFeb 22 2019 - Weekly Reports |
3 |
S&P500: Breather DueFeb 22 2019 - Technicals |
4 |
ESG Focus: SASB Takes On The World In 2019Feb 22 2019 - ESG Focus |
5 |
The Overnight Report: Details EmergeFeb 22 2019 - Daily Market Reports |
Most Popular
1 |
Rudi’s View: The Year Of Shame (Part 2)Jan 25 2019 - Rudi's View |
2 |
ResMed Judged Harshly As Costs MountJan 30 2019 - Australia |
3 |
Uranium Week: Utilities On The MoveJan 29 2019 - Weekly Reports |
4 |
Big Gold Run AheadFeb 01 2019 - Commodities |
5 |
Rudi’s View: The Year Of Shame (Part 1)Jan 24 2019 - Rudi's View |
6 |
ResMed To StallFeb 05 2019 - Technicals |